Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population.
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
The Brief Repeatable Battery: psychometrics and normative values with age, education and gender corrections in a Serbian population.
Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection-a case report.
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
Ono to enter license agreements with Merck KGaA
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
A practical review of the neuropathology and neuroimaging of multiple sclerosis.
New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients
Genmab announces details of planned ofatumumab Phase II study in multiple sclerosis
Stress and the risk of multiple sclerosis.
Confounding in association studies: month of birth and multiple sclerosis.
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
Sex-related factors in multiple sclerosis susceptibility and progression.
Shorter washout reduces MS relapse switching off natalizumab
Moving towards the pan-European unification of Multiple Sclerosis Nurses: a consensus paper.
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Validation of a Dutch version of the Neurological Fatigue Index (NFI-MS) for patients with multiple sclerosis in the Netherlands.
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
[Infections and fingolimod].

Pages